Yemaachi Biotech

Clinical disease activity in autoimmune rheumatic patients receiving COVID-19 vaccines

Our research on the COURAGE cohort of our Heritage Study has been published in BMC Rheumatology! The COvid-19 vaccine immUne Response in Autoimmune rheumatic patients: a Ghanaian Experience (COURAGE) study, led by Dr. Ida Dzifa Dey, followed 38 patients with Systemic lupus erythematous (SLE) and Rheumatoid arthritis (RA) over 12 months at Korle-Bu Teaching Hospital, to access changes in clinical disease activity following COVID-19 vaccination, and to understand vaccine immune response in this subset.

Liquid Biopsy – The necessary first step towards democratising precision oncology?African biotech holds the key to transforming not just the health of African people, but our economies as well

While IHC and imaging are useful for diagnosing and staging cancers, they are limited in their ability to inform clinical decision-making regarding the use of increasingly available targeted therapies that are revolutionising cancer care in developed countries. For this, more advanced molecular tests are required, and next generation sequencing-based liquid biopsy tests are at the cutting edge.

Global team to study international differences in COVID-19 immunity

Supported by £3.1 million from the Wellcome Trust, the newly-created WWW Consortium links three leading studies in West Africa (Yemaachi Biotech Heritage Study), the West Indies (Windfall Study in Kingston, Jamaica), and West London (the Legacy Study), each tracking how both the virus and our immunity has evolved against COVID-19.